Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Jon Weston
Advertisement
Jon Weston is the president and CEO of PhotonPharma.
Articles by Jon Weston
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
4
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
5